ReviewFrontiers in genetics2023
Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis.
Review in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Identification and assessment ofOncology letters · 2026Article
- Article
- Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples.British journal of cancer · 2026Article
- Challenges in early detection and prognostication of sepsis: new approaches from the emergency department and intensive care unit.EClinicalMedicine · 2026Review
- New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026Review
- Artificial Intelligence in Transcriptomics: From Human-in-the-Loop to Agentic AI.Journal of personalized medicine · 2026Review
- OnCorr: A pan-cancer mRNA-protein correlation tool for precision oncology.NPJ precision oncology · 2026Article
- Sepsis biomarkers: recent advances and future perspectives.Frontiers in immunology · 2026Review
- Whole tumor transcriptome: a possibility for diagnosis, prognosis, and therapy in precision oncology using computational analysis.Frontiers in medicine · 2026Article
- Generating crossmodal gene expression from cancer histopathology improves multimodal AI predictions.Nature communications · 2025Article
- The Latest Advances in Omics Technology for Assessing Tissue Damage: Implications for the Study of Sudden Cardiac Death.International journal of molecular sciences · 2025Review
- Evaluating the InSignia IFI27 expression assay for detecting viral respiratory infection compared to a traditional gene normalisation assay.Scientific reports · 2025Article
- Advocating for the recognition of underlying immunosuppression in critical illness.EClinicalMedicine · 2025Review
- Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.Nature communications · 2025Article
- Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility.BioMedicine · 2025Review
- Bacteria and host: what does this mean for sepsis bottleneck?World journal of emergency medicine · 2025Review
- Gene Expression Dysregulation in Whole Blood of Patients withInternational journal of molecular sciences · 2024Article
- Special Issue "Transcriptomics in the Study of Insect Biology".International journal of molecular sciences · 2024Article
- Sepsis pathogenesis and outcome are shaped by the balance between the transcriptional states of systemic inflammation and antimicrobial response.Cell reports. Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostics require precision and predictive ability to be clinically useful. Integration of multi-omic with clinical data is crucial to our understanding of disease pathogenesis and diagnosis. However, interpretation of overwhelming amounts of information at the individual level requires sophisticated computational tools for extraction of clinically meaningful outputs. Moreover, evolution of technical and analytical methods often outpaces standardisation strategies. RNA is the most dynamic component of all -omics technologies carrying an abundance of regulatory information that is least harnessed for use in clinical diagnostics. Gene expression-based tests capture genetic and non-genetic heterogeneity and have been implemented in certain diseases. For example patients with early breast cancer are spared toxic unnecessary treatments with scores based on the expression of a set of genes (e.g., Oncotype DX). The ability of transcriptomics to portray the transcriptional status at a moment in time has also been used in diagnosis of dynamic diseases such as sepsis. Gene expression profiles identify endotypes in sepsis patients with prognostic value and a potential to discriminate between viral and bacterial infection. The application of transcriptomics for patient stratification in clinical environments and clinical trials thus holds promise. In this review, we discuss the current clinical application in the fields of cancer and infection. We use these paradigms to highlight the impediments in identifying useful diagnostic and prognostic biomarkers and propose approaches to overcome them and aid efforts towards clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.